MRI scan with AI to spot early changes in NF1 children
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study uses special MRI scans plus computer (AI) analysis to look for early, possibly cancer-related skin or tissue changes in children with neurofibromatosis type 1 (NF1). If it works, it could help doctors detect concerning changes earlier and plan care sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 5 and under 18 years old when the study starts (turning 18 during the study is allowed).
- Have a confirmed diagnosis of NF1 (including mosaic/segmental NF1).
- Be able to get the MRI without needing sedation (sleeping medicine).
- Not have certain metal- or magnet-related implants, devices, or metal fragments in the body.
- Be able to complete the scan despite claustrophobia (fear of enclosed spaces) and be able to lie on your back facing upward.
- Not have an allergy to animal dander or asthma that is triggered by animals.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for better ways to measure how much tumor activity people with neurofibromatosis type 1 (NF1) have over time. The goal is to develop “biomarkers,” which are test results that may help doctors track disease more easily.
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
This study is looking for adults with NF1 who have had a plexiform neurofibroma. It aims to find better ways to detect tumors early, which could help with treatment decisions.
This study follows people with neurofibromatosis type 2 (NF2) over time to learn how the condition changes, using repeat MRI scans. The information may help researchers understand disease patterns and improve future treatments.
This study monitors people with neurofibromatosis type 1 (NF1) over time to watch for signs that their nerve tumors might turn into cancer. It helps researchers learn which tumors are more likely to change and may lead to better care.
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
Hear when a new Neurofibromatosis Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.